In AML, a growing body of evidence has demonstrated dysregulated NF-κB [22] and opened up the possibility of targeting this pathway; here, proteasome inhibitors are constituting a promising group of drugs with broad application to many types of cancers. Here, NFKB1 is linked to acute myeloid leukemia.